FI107808B - Förfarande för att identifiera en individ med risk för blodkärls- samt cancersjukdom - Google Patents

Förfarande för att identifiera en individ med risk för blodkärls- samt cancersjukdom Download PDF

Info

Publication number
FI107808B
FI107808B FI991836A FI19991836A FI107808B FI 107808 B FI107808 B FI 107808B FI 991836 A FI991836 A FI 991836A FI 19991836 A FI19991836 A FI 19991836A FI 107808 B FI107808 B FI 107808B
Authority
FI
Finland
Prior art keywords
concentration
homocysteine
serum
pgi
risk
Prior art date
Application number
FI991836A
Other languages
English (en)
Finnish (fi)
Other versions
FI19991836A (sv
Inventor
Osmo Suovaniemi
Matti Haerkoenen
Pentti Sipponen
Original Assignee
Biohit Oyj
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biohit Oyj filed Critical Biohit Oyj
Priority to FI991836A priority Critical patent/FI107808B/sv
Priority to JP2001520901A priority patent/JP2003508059A/ja
Priority to EP00956556A priority patent/EP1210452A1/en
Priority to PCT/FI2000/000733 priority patent/WO2001016356A1/en
Priority to CNB008122261A priority patent/CN1158389C/zh
Priority to RU2002107982/15A priority patent/RU2247389C2/ru
Priority to AU68456/00A priority patent/AU6845600A/en
Publication of FI19991836A publication Critical patent/FI19991836A/sv
Application granted granted Critical
Publication of FI107808B publication Critical patent/FI107808B/sv

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/82—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving vitamins or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6806—Determination of free amino acids
    • G01N33/6812—Assays for specific amino acids
    • G01N33/6815—Assays for specific amino acids containing sulfur, e.g. cysteine, cystine, methionine, homocysteine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biophysics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Claims (5)

1. Förfarande for att identifiera en individ med risk for blodkärls- och cancersjukdom, kännetecknat därav, att forfarandet omfattar stegen, i vilka 5. man bestämmer kvantitativt pepsinogen I (PGI) analytkoncentrationen Mn ett serumprov av nämnda individ, - man bestämmer ett metodspecifikt cut-off-värde for nämnda analyt, - man jämför den sä bestämda analytkoncentrationen med analytens metodspecifika cut-off-värde, och 10. man bestämmer homokysteinkoncentrationen i ett serumprov av individen och jämför den med ett metodspecifikt referensvärde för homokystein.
2. Förfarande enligt patentkravet 1, kännetecknat därav, att man ur ett serumprov Mn individen bestämmer PGI-koncentrationen och därefter homokystein- 15 koncentrationen dä serumets PGI-koncentrationen är under dess cut-off-värde.
3. Förfarande enligt patentkravet 1 eller 2, kännetecknat därav att det innehäller ocksä ett steg där man bestämmer provets B12-vitaminkoncentration och jämför den med ett metodspecifikt referensvärde. 20 .·.
4. Testförpackning för att genomföra förfarandet enligt patentkravet 1, vilken ··· • 1 · 1; förpackning innehäller • ♦ : 1: 1: - medel för att bestämma PGI-koncentrationen i ett serumprov, • · - medel för att bestämma homokysteinkoncentrationen i ett serumprov. • · · V 125
··· : 5. Testförpackning enligt patentkravet 4, i vilken medlen för att bestämma pepsinogen I och homokysteinkoncentrationen är immunologiska medel. • · • · · • · • · · • · • · · ' ·. 1:30 ··· « · • 1 • · · « • · • · t • · · • ·
FI991836A 1999-08-31 1999-08-31 Förfarande för att identifiera en individ med risk för blodkärls- samt cancersjukdom FI107808B (sv)

Priority Applications (7)

Application Number Priority Date Filing Date Title
FI991836A FI107808B (sv) 1999-08-31 1999-08-31 Förfarande för att identifiera en individ med risk för blodkärls- samt cancersjukdom
JP2001520901A JP2003508059A (ja) 1999-08-31 2000-08-30 管疾患及び癌の危険性のある人を同定する方法
EP00956556A EP1210452A1 (en) 1999-08-31 2000-08-30 Method for identifying an individual at risk for vascular and cancer disease
PCT/FI2000/000733 WO2001016356A1 (en) 1999-08-31 2000-08-30 Method for identifying an individual at risk for vascular and cancer disease
CNB008122261A CN1158389C (zh) 1999-08-31 2000-08-30 一种用于鉴别有血管及癌症疾病患病风险的个体的方法
RU2002107982/15A RU2247389C2 (ru) 1999-08-31 2000-08-30 Способ идентификации индивидуума с риском сосудистого и ракового заболевания
AU68456/00A AU6845600A (en) 1999-08-31 2000-08-30 Method for identifying an individual at risk for vascular and cancer disease

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FI991836 1999-08-31
FI991836A FI107808B (sv) 1999-08-31 1999-08-31 Förfarande för att identifiera en individ med risk för blodkärls- samt cancersjukdom

Publications (2)

Publication Number Publication Date
FI19991836A FI19991836A (sv) 2001-02-28
FI107808B true FI107808B (sv) 2001-10-15

Family

ID=8555217

Family Applications (1)

Application Number Title Priority Date Filing Date
FI991836A FI107808B (sv) 1999-08-31 1999-08-31 Förfarande för att identifiera en individ med risk för blodkärls- samt cancersjukdom

Country Status (7)

Country Link
EP (1) EP1210452A1 (sv)
JP (1) JP2003508059A (sv)
CN (1) CN1158389C (sv)
AU (1) AU6845600A (sv)
FI (1) FI107808B (sv)
RU (1) RU2247389C2 (sv)
WO (1) WO2001016356A1 (sv)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2453001C1 (ru) * 2010-10-18 2012-06-10 Государственное образовательное учреждение высшего профессионального образования "Курский государственный медицинский университет Федерального агентства по здравоохранению и социальному развитию" Способ коррекции гипергомоцистеин индуцированного дефицита оксида азота l-норвалином в эксперименте
CN114924016B (zh) * 2022-04-28 2024-03-08 中国医学科学院北京协和医院 同时检测硫酸化及未硫酸化胃泌素g17的方法及其检测试剂盒

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI97304C (sv) * 1994-11-16 1996-11-25 Locus Genex Oy Förfarande för screening av magkancerrisk

Also Published As

Publication number Publication date
FI19991836A (sv) 2001-02-28
CN1371427A (zh) 2002-09-25
RU2247389C2 (ru) 2005-02-27
CN1158389C (zh) 2004-07-21
WO2001016356A1 (en) 2001-03-08
JP2003508059A (ja) 2003-03-04
EP1210452A1 (en) 2002-06-05
AU6845600A (en) 2001-03-26

Similar Documents

Publication Publication Date Title
CA1298536C (en) Assay for sulfhydryl amino acids and methods for detecting and distinguishing cobalamin and folic acid deficiency
Ducros et al. Methods for homocysteine analysis and biological relevance of the results
JP2009520957A (ja) 便試料中のヘモグロビンおよびｍ２−ｐｋを測定することによる結腸直腸癌の評価方法
Maldonado et al. Simultaneous electrochemical measurement method of histamine and Nτ-methylhistamine by high-performance liquid chromatography–amperometry with o-phthalaldehyde–sodium sulfite derivatization
Zighetti et al. Determination of total homocysteine in plasma: comparison of the Abbott IMx immunoassay with high performance liquid chromatography
Sheabar et al. Quantitative analysis of aflatoxin-albumin adducts
US20240345100A1 (en) Diagnostic biomarker for cancer and use thereof
Umenishi et al. Comparison of three methods to quantify urinary aquaporin-2 protein
Harrington Methods for assessment of vitamin B12
Shin et al. A sensitive and specific liquid chromatography-tandem mass spectrometry assay for simultaneous quantification of salivary melatonin and cortisol: development and comparison with immunoassays
FI107808B (sv) Förfarande för att identifiera en individ med risk för blodkärls- samt cancersjukdom
US20030124616A1 (en) Homocysteinylated transthyretin
CN108896771B (zh) Guca2a蛋白在骨关节炎中的用途
Nilsson et al. Clinical utility of serum holotranscobalamin as a marker of cobalamin status in elderly patients with neuropsychiatric symptoms
Woo et al. Relationship between the levels of holotranscobalamin and vitamin B12
EP3234104A2 (en) Accurate assay measurement of hydrophobic haptenic analytes
EP1173764B1 (en) Method for identifying an individual at risk for irreversible neurodamages, comprising the steps of determining quantitatively the concentration of pepsinogen i (pgi) and vitamin b12
Tateishi et al. Stability of bombesin in serum, plasma, urine, and culture media.
Zappacosta et al. Comparing different methods for homocysteine determination
CN112595851A (zh) 一种强稳定性的同型半胱氨酸测定试剂盒及其制备方法
US7727972B2 (en) Methods for determining absorption of cobalamin or analogues thereof
Mourvaki et al. Performance comparison of three assay methods used in fasting and postmethionine load plasma homocysteine determinations from patients with vascular disease
CN115372609B (zh) 一种用于测定糖类抗原242的试剂盒及其应用
Sarma et al. Direct microtitre plate enzyme immunoassay of folic acid without heat denaturation of serum
SHINOGI et al. Measurement of metallothionein in rat tissues by a chromatographic method using the fluorometry of thiol groups